Achilles Therapeutics Ltd., of Stevenage, U.K., appointed Sergio Quezada chief scientific officer, effective April 6, 2020.
Affimed NV, of Heidelberg, Germany, appointed Arndt Schottelius chief scientific officer, effective April 2020.
Atyr Pharma Inc., of San Diego, appointed Arthur M. Mercurio scientific adviser.
Capricor Therapeutics Inc., of Los Angeles, appointed Stephen Gould executive consultant for its exosomes program.
Curevac AG, of Tubingen, Germany, appointed Franz-Werner Haas deputy CEO until the return of Ingmar Hoerr, who has taken a temporary leave of absence for medical reasons not caused by coronavirus.
Imcheck Therapeutics SAS, of Marseille, France, appointed Hans Henrik Christensen chief financial officer and chief operating officer.
Logicbio Therapeutics Inc., of Cambridge, Mass., appointed Mark Enyedy to its board.
Memgen LLC, of Houston, appointed Gregory B. Brown CEO and Robert Coates executive chairman.
Morphic Therapeutic Inc., of Waltham, Mass., appointed Peter G. Linde chief medical officer.
Recursion Pharmaceuticals Inc., of Salt Lake City, appointed Shafique Virani chief corporate development officer.